The USFDA has recently approved aprocitentan for treating adult patients with resistant hypertension in combination with other antihypertensive drugs. Aprocitentan is an endothelin receptor antagonist. Its safety and efficacy were evaluated in clinical trials.
Clinical evidence In clinical trials (PRECISION, NCT03541174) involving 730 patients, aprocitentan was well tolerated and attained superiority in reducing systolic blood pressure at week four and sustaining the effect at week 40 compared to placebo. Dosage and administration 12.5 mg; orally once daily with or without food Contraindications Pregnancy (due to embryo and fetal toxicity) Hypersensitivity Warnings and precautions Aprocitentan can cause Hepatotoxicity and liver failure Fluid retention Reduction of hemoglobin Reduction of sperm counts Adverse reactions – Edema/fluid retention and anemia Will aprocitentan be a better…
